Investor's Business Daily on MSN
How S&P drug titan Pfizer plans to outdo its own $6 billion franchise
The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results